Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

NCT00353301 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Erlotinib hydrochloride
DRUG: Sirolimus

Sponsor

University of Colorado, Denver

Collaborators

[object Object]